Company Encyclopedia
View More
name
Labcorp
LH.US
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
380.95 B
LH.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care ServicesIndustry
Industry Ranking3/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.14%B
    • Profit Margin6.21%B
    • Gross Margin28.77%C
  • Growth ScoreB
    • Revenue YoY8.28%B
    • Net Profit YoY96.37%A
    • Total Assets YoY-1.89%D
    • Net Assets YoY6.45%B
  • Cash ScoreB
    • Cash Flow Margin1609.60%B
    • OCF YoY8.28%B
  • Operating ScoreB
    • Turnover0.75B
  • Debt ScoreC
    • Gearing Ratio52.29%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Labcorp Holdings Inc. Stock Underperforms Thursday When Compared To Competitors

    Labcorp Holdings Inc. stock fell 1.61% to $261.48 on Thursday, marking its fourth consecutive day of losses. The stock underperformed compared to competitors, with IQVIA Holdings Inc. down 1.02%, Centene Corp. up 0.10%, and Teladoc Health Inc. up 3.32%. Labcorp is 10.98% below its 52-week high of $293.72. Trading volume was 861,158, above the 50-day average of 844,561.

    Dow Jones·
    US
    LH
    -1.61%
    Dow Jones·
    US
    LH
    -1.61%

    Expanding access in oncology trials: The case for a paired tissue-plasma approach

    Labcorp is promoting a paired tissue-plasma approach in oncology trials, combining tissue-based genomic profiling with liquid biopsy. This strategy enhances trial design, patient stratification, and therapy selection, while supporting companion diagnostic development. It offers non-invasive testing, expands access, and improves efficiency in drug development. Labcorp's platforms, Tissue Complete and Plasma Focus, provide broad genomic coverage and are available globally, facilitating integrated biomarker testing for clinical trials.

    biopharmadive·
    US
    LH
    -1.61%
    biopharmadive·
    US
    LH
    -1.61%

    Labcorp Holdings Inc. Files Initial Beneficial Ownership Statement for Director Victor Bulto Carulla

    Labcorp Holdings Inc. has filed an initial statement of beneficial ownership with the SEC, naming Victor Bulto Carulla as a director. This filing is accessible via EDGAR, the SEC's system. The news brief was generated by Public Technologies using AI and is for informational purposes only, not financial advice.

    Reuters·
    US
    LH
    -1.61%
    Reuters·
    US
    LH
    -1.61%

    CHS Sells Select Outreach Laboratory Assets to Labcorp for $194 Million

    Community Health Systems, Inc. has sold select ambulatory outreach laboratory service assets to Labcorp for $194 million. The sale includes patient service centers and in-office phlebotomy locations across 13 states. CHS will continue to operate inpatient and emergency department laboratories. This transaction aims to expand access to Labcorp’s services and allow CHS to focus on core services.

    Reuters·
    US
    LH
    -1.61%
    US
    CYH
    +1.68%
    Reuters·
    US
    LH
    -1.61%
    US
    CYH
    +1.68%

    Should You Continue to Hold LH Stock in Your Portfolio?

    Labcorp continues to expand its business in specialty testing areas and benefits from strategic partnerships and solid financial stability. Despite macroeconomic challenges and currency impacts, the company has shown strong earnings performance and has been active in acquisitions and share repurchases. The article suggests considering holding LH stock while also highlighting other strong healthcare stocks.

    TradingView·
    US
    LH
    -1.61%
    TradingView·
    US
    LH
    -1.61%
    © 2025 Longbridge｜Disclaimer